Focal Healthcare’s Fusion Bx™ 2.0 leverages the sensitivity of multiparametric MRI and the practicality of ultrasound to provide radiologists and urologists with a targeted approach for detecting prostate cancer.
Fusion Bx 2.0 features:
• A semi-robotic arm that keeps the probe steady to ensure consistent pressure on the prostate, limiting movement and deformation, thereby leading to increased accuracy • A 3D model that allows the physician to visualize the prostate and MRI targets in real-time to guide the biopsy needle to the regions of interest • Automatic motion compensation which adjusts for patient movement to maintain image registration, allowing procedures to continue uninterrupted • A step-by-step guided workflow combined with semi-automatic segmentation that enables physicians to perform procedures in less time and with minimal training
• Support for both transperineal and transrectal approaches with the same equipment and workflow
Fusion Bx 2.0 is FDA cleared and CE marked, and is available for sale in Canada, USA, the EU, Taiwan and Hong Kong.